Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind trial of SJP-0132 ophthalmic suspension in Chinese patients with dry eye disease
CTR20244132Phase 3Completed
- Sponsor
- Senju Pharmaceutical Co., Ltd.
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dry eye syndrome (DED) comparing SJP-0132 ophthalmic suspension with Placebo ophthalmic solution (2 arms). Primary endpoints: Change in corneal fluorescein staining score from baseline at Day 29 and Change in ocular dryness VAS score from baseline at Day 8. Started Nov 2024; status: completed.
02
Drugs
motsugibatorep
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on CTR20244132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244132.